Pharmacokinetics (PK) study of meropenem in Epithelial Lining Fluid (ELF), an open-label study

Trial Profile

Pharmacokinetics (PK) study of meropenem in Epithelial Lining Fluid (ELF), an open-label study

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 May 2016

At a glance

  • Drugs Meropenem (Primary)
  • Indications Bacterial infections; Community-acquired pneumonia; Febrile neutropenia; Skin and soft tissue infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 17 Feb 2016 Status changed from recruiting to active, no longer recruiting.
    • 02 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top